{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:15:10Z","timestamp":1790234110317,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","jocn-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jocn.2017.08.006","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T01:31:27Z","timestamp":1503624687000},"page":"257-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population"],"prefix":"10.1016","volume":"45","author":[{"given":"I.","family":"Correia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jesus-Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.I.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Mac\u00e1rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2017.08.006_b0005","series-title":"Progressive Multifocal Leukoencephalopathy","article-title":"Progressive Multifocal Leukoencephalopathy: current concepts of a renewed disease","author":"Correia","year":"2015"},{"issue":"3","key":"10.1016\/j.jocn.2017.08.006_b0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11910-006-0013-z","article-title":"Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab","volume":"6","author":"Langer-Gould","year":"2006","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.jocn.2017.08.006_b0015","unstructured":"Biogen. [Available from: https:\/\/medinfo.biogen.com\/secure\/download?doc=workspace%3A%2F%2FSpacesStore%2Fded9df8f-d785-444a-ae89-888bef72aa7e&type=pmldoc&path=null&dpath=null&mimeType=null."},{"issue":"4","key":"10.1016\/j.jocn.2017.08.006_b0020","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.msard.2014.01.005","article-title":"Progressive multifocal leukoencephalopathy and JC virus-related disease in modern neurology practice","volume":"3","author":"Carruthers","year":"2014","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.jocn.2017.08.006_b0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/WCO.0b013e328360279f","article-title":"Progressive multifocal leukoencephalopathy in patients with multiple sclerosis","volume":"26","author":"Baldwin","year":"2013","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"10.1016\/j.jocn.2017.08.006_b0030","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1212\/WNL.0000000000002330","article-title":"Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay","volume":"86","author":"Gagne Brosseau","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jocn.2017.08.006_b0035","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.jocn.2017.08.006_b0040","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1","volume":"70","author":"Bozic","year":"2011","journal-title":"Ann Neurol"},{"issue":"22","key":"10.1016\/j.jocn.2017.08.006_b0045","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0b013e3182583022","article-title":"Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort","volume":"78","author":"Trampe","year":"2012","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jocn.2017.08.006_b0050","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00415-012-6487-5","article-title":"Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy","volume":"259","author":"Outteryck","year":"2012","journal-title":"J Neurol"},{"issue":"11","key":"10.1016\/j.jocn.2017.08.006_b0055","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult Scler"},{"issue":"1\u20132","key":"10.1016\/j.jocn.2017.08.006_b0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jns.2013.11.031","article-title":"JCV epidemiology in MS (JEMS)\u2013epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients\u2013Portuguese data","volume":"337","author":"da Silva","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2017.08.006_b0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jns.2016.03.050","article-title":"Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain","volume":"365","author":"Aladro","year":"2016","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.jocn.2017.08.006_b0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jocn.2017.08.006_b0075","article-title":"Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy","volume":"2","author":"Salmen","year":"2016","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"S11","key":"10.1016\/j.jocn.2017.08.006_b0080","first-page":"654","article-title":"Variability of John Cunningham virus (JCV) index in multiple sclerosis patients treated with natalizumab in routine clinical practice","volume":"21","author":"Arndt","year":"2015","journal-title":"Mult Scler"},{"issue":"S1","key":"10.1016\/j.jocn.2017.08.006_b0085","first-page":"285","article-title":"Anti-JC virus antibodies in a Portuguese multiple sclerosis cohort","volume":"20","author":"Correia","year":"2014","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.jocn.2017.08.006_b0090","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"Schwab","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"10.1016\/j.jocn.2017.08.006_b0095","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1352458513505353","article-title":"JC-virus seroconversion in multiple sclerosis patients receiving natalizumab","volume":"20","author":"Outteryck","year":"2014","journal-title":"Mult Scler"},{"issue":"14","key":"10.1016\/j.jocn.2017.08.006_b0100","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1177\/1352458515599681","article-title":"Anti-JC virus antibody titres increase over time with natalizumab treatment","volume":"21","author":"Raffel","year":"2015","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.jocn.2017.08.006_b0105","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/ene.12988","article-title":"High cumulative JC virus seroconversion rate during long-term use of natalizumab","volume":"23","author":"Vennegoor","year":"2016","journal-title":"Eur J Neurol"},{"issue":"11","key":"10.1016\/j.jocn.2017.08.006_b0110","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/jnnp-2012-304332","article-title":"Changes to anti-JCV antibody levels in a Swedish national MS cohort","volume":"84","author":"Warnke","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.jocn.2017.08.006_b0115","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/ane.12475","article-title":"Anti-JC virus seroprevalence in a Finnish MS cohort","volume":"133","author":"Kolasa","year":"2016","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"10.1016\/j.jocn.2017.08.006_b0120","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1128\/JVI.00131-13","article-title":"Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy","volume":"87","author":"Hendel-Chavez","year":"2013","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.jocn.2017.08.006_b0125","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab","volume":"361","author":"Chen","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jocn.2017.08.006_b0130","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1212\/NXI.0000000000000199","article-title":"Rising JCV-Ab index during natalizumab therapy for MS: inauspicious for a highly efficacious drug","volume":"3","author":"Javed","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10.1016\/j.jocn.2017.08.006_b0135","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1177\/1352458513477229","article-title":"Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients","volume":"19","author":"Selter","year":"2013","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.jocn.2017.08.006_b0140","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/1352458514556296","article-title":"Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF","volume":"21","author":"Warnke","year":"2015","journal-title":"Mult Scler"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586816311882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586816311882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T10:34:24Z","timestamp":1549794864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586816311882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":28,"alternative-id":["S0967586816311882"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2017.08.006","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2017.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}